Summary: Tebipenem pivoxil (TBPM-PI, ME1211) has been under development as the world's first oral carbapenem for treatment of otolaryngological/respiratory infections caused by drug-resistant S. pneumoniae in pediatric patients. In order to treat these infections effectively, it is important to design optimal dosing regimens based on the pharmacokinetics/pharmacodynamics (PK/PD) relationships, which can be characterized by clarifying the pharmacokinetics of tebipenem (TBPM) in the pediatric population.
Introduction
Tebipenem pivoxil (TBPM-PI, ME1211), a prodrug of an oral carbapenem antibiotic, is likely to become a specific antibiotic for treatment of persistent otitis media, upper respiratory infection and bacterial pneumonia in pediatric patients. TBPM-PI has just been applied for registration as a new drug for treatment of pediatric patients. Both the clinical efficacy rates and the biological eradication rates of TBPM-PI after administration at 4 or 6 mg/kg b.i.d. for 8 days were 90% or higher in the Phase II and Phase III studies, which were conducted to treat pediatric patients with pediatric/otolaryngological infection or bacterial pneumonia. 1, 2) From the viewpoint of clinical and biological efficacy, the dosage conditions were considered to be adequate. However, investigation into the pharmacokinetics/pharmacodynamics (PK/PD) relationships based on the antibacterial activity and exposure of antibiotics is essential to establish an optimum dosage regimen and to design appropriate individualized dosing of antibiotics. [3] [4] [5] In other words, repeated exploration and verification of the pre-clinical in vivo PK/PD studies, pharmacokinetic profiles of the drug in healthy volunteers and/or targeted patient population, and the efficacy and safety in clinical studies are indispensable for establishing an optimum dosage regimen during the drug development program. 3, 5) So, it is important to corroborate the dosage conditions in the Phase II and Phase III studies of TBPM-PI using the PK/PD relationships based on antibacterial activity and pharmacokinetics of Tebipenem (TBPM, LJC11,036), an active form of TBPM-PI.
TBPM exhibits a broad-spectrum activity and possesses an antibacterial activity superior to that of b-lactam antibiotics currently available on the market, when tested against almost all clinically isolated pathogenic bacteria excluding Pseudomonas aeruginosa. Furthermore, TBPM exhibits antibacterial activity equal or superior to current clinically available carbapenems. 6, 7) In particular, TBPM possesses a strong antibiotic activity (MIC90＝0.1 mg/mL) against penicillin-resistant S. pneumoniae (PRSP), a pathogen that causes intractable pediatric otitis media. TBPM also possesses a good antibiotic activity (MIC90＝0.39 mg/mL) against Haemophilus influenzae (H. influenzae), a pathogen causing respiratory infection, and against b-lactamase-producing pathogens resistant to penicillin and cephalosporin antibiotics. 6) Since TBPM is stable when exposed to human dehydropeptidase-I (hDHP-I), which is known to degrade carbapenems, 6) it can be used without a stabilizer.
TBPM-PI was synthesized as a prodrug, a pivaloyloxymethyl ester that improves oral absorption. TBPM-PI is rapidly and stoichiometrically converted to TBPM in the small intestine after oral administration and moves into the systemic circulation. In the Phase I study, TBPM-PI was absorbed rapidly after oral administration in healthy volunteers, resulting in a relatively high maximum plasma concentration of the active form, and rapid excretion into urine as the active form, with a recovery rate of about 70%. 8) TBPM thus has good pharmacokinetic features. There is, however, marked inter-individual physiological variation in children, and it is important to clarify the pharmacokinetics of TBPM in the pediatric population (0.5-16 years old) from an early stage of development, in order to recommend an appropriate dosage regimen of the drug immediately on release onto the market. Population pharmacokinetic analysis is useful for clarifying the pharmacokinetic features of a drug in a special population, such as pediatric population, in which frequent blood sampling is ethically difficult. 9) Moreover, population pharmacokinetic analysis reveals the influence of covariates (background data) on the pharmacokinetics of the drug, and provides useful information to design appropriate individualized dosage regimen. 10) We therefore performed a population pharmacokinetic analysis using plasma TBPM concentrations that were obtained in the Phase II and Phase III studies (4 or 6 mg/kg b.i.d. of oral TBPM-PI for 8 days). 1, 2) These studies were conducted to evaluate the pharmacokinetics, effectiveness and safety of TBPM in pediatric patients with otolaryngological infection or bacterial pneumonia. We then obtained population pharmacokinetic parameters for TBPM. In addition we estimated individual primary pharmacokinetic parameters (ka, CL/F, Vd/F, and Tlag) of TBPM for each pediatric patient using a Bayesian method, and compared secondary pharmacokinetic parameters (Tmax, Cmax, AUC0-24h and t1/2) among three age groups (0.5-3, 3-6 and 6-16 years old).
Finally, we complemented the appropriateness of the dosage condition (4 or 6 mg/kg b.i.d.) of TBPM-PI, which was adopted in the abovementioned clinical studies, from the viewpoint of PK/PD evaluation. In addition, we proposed a method to make sure that the dosage condition results in achieving sufficient efficacy in treating each patient, using the presently obtained results of population pharmacokinetic analysis.
Materials and Methods
Data for analysis: Five clinical studies (Phase II and Phase III) of TBPM-PI were performed in pediatric patients with pediatric/otolaryngological infection or bacterial pneumonia between January 2005 and April 2007 in Japan (Table 1) .
1,2)
These studies were all performed in accordance with the Declaration of Helsinki, the ethics committee approval, and the informed consent of all patients' parents. These studies were carefully carried out, with the safety and efficacy of TBPM-PI being confirmed and with higher age groups preceding lower age groups and lower dosage group (4 mg/kg b.i.d. for 8 days) preceding higher dosage group (6 mg/kg b.i.d. for 8 days) for study subjects. TBPM-PI was orally administered as fine granules. In the population pharmacokinetic analysis, we enrolled a total of 217 patients for whom demographic background data and at least one detectable plasma TBPM concentration were obtained. Plasma samples, whose TBPM concentrations were below the limit of quantification (LOQ), were excluded from the analysis. In total, 395 plasma TBPM concentrations were determined and shown together with the time from TBPM-PI administration to blood sampling (Fig. 1) . Of these patients, 152 (229 points) were enrolled in pediatric/ otolaryngological studies and 65 (166 points) participated in the studies of bacterial pneumonia ( Table 1) . One hundred and fifty two patients (256 points) were given TBPM-PI at a dose of 4 mg/kg for 8 days, and 65 patients (139 points) received 6 mg/kg for 8 days. The numbers of patients, from whom blood samples were taken on the day of administration, and 1, 2, 3, 4, 5, 6 and 7 days after the administration of TBPM-PI, were 35, 28, 24, 34, 17, 4, 38 and 37, respectively.
Demographic data of patients: The gender, age (in years), height (HT, cm), body weight (WT, kg), serum creatinine concentration (Scr, mg/dL), weight-normalized creatinine clearance (Ccr, mL/min/kg) and clinical diagnosis were used in the analysis. The predictive equations The predictive formula for the GFR of children from one to 18 years old by Scott 12) is: Assuming the Ccr equals to the GFR, the predictive equation for the weight-normalized Ccr of infants under one year old is derived from Equations 1, 3 and 4:
Ccr(mL/min/kg)＝0.00187×HT Table 2) , respectively.
Assay of plasma tebipenem concentrations: Plasma TBPM concentrations were determined by liquid chromatography coupled with a mass spectrometer system (LC/MS/MS), composed of a high performance liquid chromatography (Alliance 2690 separation module, Waters Corporation, Milford, MA, USA), mass spectrometer (Finnigan TSQ 7000, Thermo Fisher Scientific, Inc., Waltham, MA, USA) and software (Xcalibur, Thermo Fisher Scientific, Inc.).
The MOPS (3-Morpholinopropanesulfonic acid) treated samples were prepared by adding 1 mol/L MOPS buffer (pH 7.0) and blank human plasma to plasma samples. The MOPS-treated sample was deproteinized by adding acetonitrile, followed by addition of internal standard and centrifugation. TBPM was extracted from the supernatant by solid extraction using preconditioned Empore Universal Resin (1.2 mL Extraction Disk Plates, 3M Company, Maplewood, MN, USA). The extract was diluted with purified water and injected into the LC/MS/MS system. TBPM was chromatographically separated at room temperature in an analytical column (Inertsil Ph-3, 33 mm×2.1 mm i.d., 5 mm, GL Sciences Inc., Tokyo, Japan) using a gradient of 20 mmol/L ammonium acetatemethanol as the mobile phase. TBPM was detected by Electrospray ionization mass/mass spectrometry (ESI-MS/MS) (Multiple Reaction Monitoring, m/z 384ª298). The lower limit of quantification of the present assay was 0.05 mg/mL. The precision (percentage coefficient of variation; %CV) of the assay method was 18.7%, 9.1%, 4.0% and 6.1% at 0.05, 0.1, 1 and 16 mg/mL, respectively.
Population pharmacokinetic analysis, empirical Bayesian estimation of pharmacokinetic parameters and model validation: Population pharmacokinetic analysis was performed to obtain the population means of pharmacokinetic parameters, inter-subject variations in these parameters, and residual variability between the observed and the predicted plasma TBPM concentrations. A one-compartment model with first-order absorption was used as the pharmacokinetic model. A relative error model was applied for inter-subject variation in the pharmacokinetic parameters and an additive error model was used for residual variation. The following software and hardware were used in the analysis: NONMEM (Ver. V, Level 1.0, GloboMax ICON Development Solutions, Ellicott, MD, USA), NMTRAN, and the PREDPP subroutine library (Ver. IV, Level 1.0). The subroutines ADVAN2 and TRANS2 were used in the PREDPP subroutine library. Digital Visual Fortran (Ver. 6.1, Intel Corporation, CA, USA) was used as a compiler. The personal computer used was an HP-dc5100 (Hewlett-Packard Company, Palo Alto, CA, USA) (PC/AT interchangeable, CPU: Celeron 2.80 GHz, memory 504 MB, Operating system: Windows XP).
Pharmacokinetic parameters were preliminarily estimated for each pediatric patient by population pharmacokinetic analysis, followed by Bayesian estimation using the following two kinds of Basic Models. 1) The primary pharmacokinetic parameters were first-order absorption rate constant (ka, hr -1 ), unnormalized apparent clearance (CL/F_un, L/hr), unnormalized apparent volume of distribution (Vd/F_un, L) and absorption lag time (Tlag, hr), with dosage being transformed to amount per whole body (mg/man) (Basic Model 1).
2) The primary pharmacokinetic parameters were first-order absorption rate constant (ka, hr -1 ), weight-normalized apparent clearance (CL/F, L/hr/kg), weight-normalized apparent volume of distribution (Vd/F, L/kg) and absorption lag time (Tlag, hr), with dosage being amount per body weight (mg/kg) (Basic Model 2).
The fixed effects model was constructed by investigating the relationship between the individual primary pharmacokinetic parameters, preliminarily estimated using the abovementioned two kinds of Basic Models, and demographic background data of each patient. Finally, we set up the Full Model as follows:
Full Model [11] [12] [13] which predicted weight-normalized Ccr values for children.
The fixed effects model was optimized by the likelihood ratio test using the minimum values of the objective function (OBJ; -2 log likelihood) produced by the NONMEM program. The fixed effect parameter (ui) whose removal resulted in an insignificant increase in the objective function (a change of no more than 3.84 [a＝ 0.05, 1 degree of freedom, x 2 -test]) was removed from the model. This process was repeated. Then the Final Model was established by removing all insignificant fixed effect parameters from the Full Model.
Using this Final Model, the population pharmacokinetic parameters of TBPM were obtained in pediatric patients. The empirical Bayesian estimates of pharmacokinetic parameters (ka; elimination rate constant, kel＝(CL/F)/(Vd/F); Vd/F and Tlag) were also determined for each patient by means of the post hoc option of the NONMEM estimation step, using the population pharmacokinetic parameters of the Final Model.
The validity of the Final Model was confirmed by the following two procedures; 1) Two hundred data sets were reconstructed by re-sampling from the original data set.
14)
The Final Model was fitted repeatedly to the 200 additional bootstrap data sets. The number of replications, in which calculations completed with successful minimization, was tallied up to obtain the successful calculation ratio. The mean (Mean; or bootstrap mean), median value (Median) and the empirical 95% two-tailed confidence interval (Empirical bootstrap 95% CI) for each parameter estimate, were obtained from the bootstrap replications in which the calculations were successfully completed. Then the values were examined to determine whether they were similar to the final parameter estimates obtained from the original data set. 2) Correspondence was noted between the observed plasma TBPM concentrations and the plasma TBPM concentrations, which were predicted based on the pharmacokinetic parameters estimated by Bayesian method. The weighted residuals between the observed plasma TBPM concentrations and the plasma TBPM concentrations, which were predicted based on the population mean parameters, were plotted against the predicted plasma TBPM concentration and noted.
Calculation of the secondary pharmacokinetic parameters: The secondary pharmacokinetic parameters, time to reach maximum plasma TBPM concentration (Tmax), maximum plasma TBPM concentration (Cmax), area under the plasma TBPM concentration-time curve in the interval 0-24 hour after administration (AUC0-24h) and elimination half life (t1/2), at steady state, were calculated as follows on the basis of the dose (Dose: mg/kg), dosage interval (t: hr) (＝12 hr), and the empirical Bayesian estimates of the pharmacokinetic parameters (ka, kel, Vd/F and Tlag) determined by means of the post hoc option of the NONMEM estimation step for each patient.
The averages of the secondary pharmacokinetic parameters were compared in the 4 and 6 mg/kg dosage groups over the whole age range using Student's t-test. Multiple comparisons were conducted between the averages of the secondary pharmacokinetic parameters in the 0.5-3, 3-6 and 6-16 years old groups using Dunnett's test (control group; 6-16 years old) at 4 and 6 mg/kg, respectively.
Results
Population pharmacokinetic analysis, empirical Bayesian estimation of pharmacokinetic parameters and model validation: TBPM-PI was administered orally to 217 patients twice a day at 4 mg/kg or 6 mg/kg for 8 days, and 395 plasma TBPM concentrations were measured (Fig. 1) . The average number of determi- (Fig. 1) . Various pairs of data points, derived from patient demographic data, were plotted graphically (Fig. 2) . We confirmed that height and weight increased with age. Inter-subject variability of the weight-normalized Ccr, calculated based on HT, WT, Scr and Age, was relatively large in patients under six years old.
The OBJ values obtained by performing population pharmacokinetic analysis using the Basic Model 1 and the Basic Model 2 were 707.238 and 590.177, respectively. The OBJ value of the latter was smaller than the former by 117.061 (Table 3) . We examined the relationship between patient demographic data and individual pharmacokinetic parameters (CL/F_un and Vd/F_un) estimated by Bayesian methods using the population pharmacokinetic parameters obtained by the Basic Model 1. The CL/F_un (L/hr) tended to increase with weight, age and unnormalized Ccr, while the Vd/F_un (L) tended to increase with weight and age (Fig. 3) . On the other hand, we examined the relationship between patient demographic data and individual pharmacokinetic parameters (weight-normalized apparent clearance; CL/F and volume of distribution; Vd/F) estimated by Bayesian methods using the population pharmacokinetic parameters obtained by the Basic Model 2. The CL/F (L/hr/kg) tended to increase with weight-normalized Ccr, while it was not affected by weight and age. The Vd/F (L/kg) showed a tendency to decrease with age (Fig. 4) .
The significance of each parameter ui in the Full Model shown by Equations 7-10 was tested in order to optimize the fixed effects model. The u4 (effect of difference of disease type on CL/F) and u7 (effect of difference of disease type on Vd/F) parameters were judged to be insignificant, and thus excluded from the Full Model in constructing the Final Model ( Table 3) .
Population pharmacokinetic analysis was performed using the established Final Model to calculate the population pharmacokinetic parameters of TBPM in pediatric -0.132 (L/kg) and 0.239 (hr), respectively. Intersubject variability of v(ka), v(CL/F), v(Vd/F) and v(Tlag), was 113%, 20.2%, 74.7% and 145%, respectively. The residual error (s) was 0.453 mg/mL.
The Final Model was validated using the bootstrap method. Calculations were completed successfully in 193 out of 200 bootstrap trials, with a success ratio of 96.5%. The mean and median of each parameter estimate derived from the bootstrap replications were similar to the final parameter estimates obtained from the original data set using the Final Model ( Table 5 ). The observed plasma TBPM concentrations were plotted against the predicted plasma TBPM concentrations calculated on the basis of individual pharmacokinetic parameters estimated by Bayesian method, showing many points distributed around the line of unity. The weighted residuals between the observed plasma TBPM concentrations and the predicted plasma TBPM concentrations calculated on the basis of population mean parameters and individual background data were almost within the range of ±3 (Fig. 5) . In addition the correspondence between plasma TBPM concentrations predicted by the Bayesian method and observed plasma TBPM concentrations was generally good in each patient (data not shown). The population pharmacokinetic parameters of TBPM in pediatric patients obtained in this study were demonstrated to be robust and precise.
Calculation of the secondary pharmacokinetic parameters: The secondary pharmacokinetic parameters, Tmax, Cmax, AUC0-24h and t1/2, were calculated on the basis of individual Bayesian estimates of the primary pharmacokinetic parameters (ka, kel, Vd/F and Tlag) in the 4 mg/kg and 6 mg/kg dosage groups ( Table 6 ). Across the entire age range, Tmax values were 0.74±0.26 and 0.69±0.22 hr (average±standard deviation) and t1/2 values were 1.05±0.68 and 0.99±0.50 hr in the 4 mg/kg and 6 mg/kg dosage groups, respectively. The values in both dosage groups were similar. On the other hand, Cmax values were 3.48±1.67 and 5.20±2.84 mg/mL, and the AUC0-24h values were 11.00±1.84 and 16.07±3.35 mg･hr/mL in the 4 and 6 mg/kg dosage groups, respectively. Values increased almost in propor- Although Cmax values at a dose of 4 mg/kg did not differ among the three age groups, the Cmax values in the groups aged 0.5-3 and 3-6 years (4.44±2.02 and 4.81±2.07 mg/mL) were significantly smaller than those in the group aged 6-16 years (7.48±4.28 mg/mL) at 6 mg/kg (p＝0.002 and 0.007, Dunnett's test). The AUC0-24h values in the groups aged 0.5-3 and 3-6 years (10.23±1.54 and 10.93±1.89 mg･hr/mL) were significantly smaller than those in the group aged 6-16 years (12.01±1.61 mg･hr/mL) at 4 mg/kg ( *** pº0.001 and p＝0.004, Dunnett's test). The AUC0-24h value in the group aged 0.5-3 years (14.91±2.30 mg･hr/mL) was significantly smaller than that in the group aged 6-16 years (18.30±5.70 mg･hr/mL) at 6 mg/kg (p＝0.005, Dunnett's test) ( Table 6 ). The AUC0-24h values in the younger age groups (0.5-3 and 3-6 years) were lower than those in the older age group (6-16 years) by 10-20%.
Discussion
Recently, S. pneumoniae resistant to penicillin (PRSP) has been rapidly increasing worldwide, resulting in more patients with persistent acute otitis media or prolonged or recurrent acute upper respiratory infections, particularly in pediatrics. 1) Because there is no oral antibiotic on the market that has a definite clinical effect in these infections, it has become more and more difficult to treat such infections in a hospital outpatient setting. Such patients are more likely to be hospitalized and to receive treatment with intravenous antibiotics. TBPM has good bacteriological features such as strong antimicrobial activity against PRSP, H. Influenzae and b-lactamaseproducing pathogens. 6) Moreover, TBPM has good pharmacokinetic features such as good absorption 8, 15, 16) and sufficient stability against hDHP-I in its active form. 6) If this antibiotic is not used according to an appropriate regimen, such usage might cause emergent resistance of pathogens and worsen the clinical environment. In the light of guidelines that recommend introduction of pharmacokinetics/pharmacodynamics (PK/PD) evaluation in the clinical development of antibiotics in Europe 3) and USA, 4) and the``Clinical PK/PD Guidance (Draft)'' written by the Japanese Society of Chemotherapy, 5) a grasp of pharmacokinetic features of TBPM in pediatric patients and the PK/PD evaluation of TBPM are necessary in order to advance the clinical development of TBPM-PI for pediatric patients and to give clinicians assurance that the presently recommended dosage of TBPM-PI is appropriate once the drug is released onto the market. In open clinical studies (Phase II and Phase III) of TBPM-PI in pediatric patients, 395 data points of plasma TBPM concentration were collected from the 217 patients enrolled, allowing us to perform population pharmacokinetic analysis on these data.
At the beginning of the population pharmacokinetic analysis of TBPM, we compared a one-compartment model and a two-compartment model. We supposed that the one-compartment model should be more appropriate than the two-compartment model based on the plasma TBPM profiles (Fig. 1) . Moreover, when we performed the population pharmacokinetic analysis using the twocompartment model without covariates, calculations didn't converge appropriately (data not shown). Therefore, we selected the one-compartment model with firstorder absorption as a pharmacokinetic model. Secondly, we investigated which covariate could affect the intersubject variations in the pharmacokinetic parameters (CL/F_un, Vd/F_un, CL/F and Vd/F). We found that both of the CL/F_un (L/hr) and Vd/F_un (L), which were preliminarily calculated by the population pharmacokinetic analysis and following Bayesian estimation using the Basic Model 1, increased in proportion to weight (Fig.  3) . The OBJ value (590.177) obtained in the population pharmacokinetic analysis using Basic Model 2 was smaller than the OBJ value (707.238) obtained in the population pharmacokinetic analysis using Basic Model 1, by 117.061. In addition, the dosages (mg/kg) of TBPM-PI in pediatric patients were weight-normalized, and thus we judged that it was proper to perform population pharmacokinetic analysis on the basis of the weight-normalization of the pharmacokinetic parameters. In some papers on the population pharmacokinetic analysis of other antibiotics (Gatifloxacin, 17) Ciprofloxacin, 18) Arbekacin, 19) Meropenem, 20) Vancomycin 21) and Teicoplanin 22) ) in pediatric patients, the weight was selected as a covariate that affected the unnormalized apparent clearance (L/hr) and/or volume of distribution (L). So it was noted that the weight had much effect on the pharmacokinetics of these drugs.
The CL/F (L/hr/kg), which were preliminarily calculated by the population pharmacokinetic analysis and following Bayesian estimation using the Basic Model 2, increased in proportion to weight-normalized Ccr. The Vd/F (L/kg) tended to decrease with age. (Fig. 4) .
A Full Model was constructed as follows. Based on the abovementioned findings, we created the hypothetical Equation 8, in which the CL/F (L/hr/kg) of TBPM increased in proportion to weight-normalized Ccr, a consequence of TBPM being mainly excreted unchanged into urine. 8) To directly correlate the CL/F of TBPM and weight-nor-malized Ccr, we derived Equations 5 and 6, which predicted weight-normalized Ccr (mL/min/kg), based on the DuBois formula that estimates body surface area based on weight and height. 13) Height is rarely measured in the clinical setting, and it is therefore usually impossible to calculate body surface area of a pediatric patient. We are certain that weight-normalized formulae for CL/F and Ccr would facilitate use of the population pharmacokinetic parameters obtained in the present study.
Likewise, we created Equation 9, which shows the Vd/F (L/kg) of TBPM decreasing as an exponential function of age. In general, the distribution volume of b-lactam antibiotics is almost the same as the ratio of extracellular fluid volume to body weight, or about 0.3 L/kg, 23) and the ratio of extra-cellular fluid volume to body weight decreases during childhood as age increases. 24) This is consistent with Equation 9. Arbekacin, an aminoglycoside antibiotic, is highly hydrophilic and mainly excreted unchanged into urine just like TBPM. Population pharmacokinetic parameters for ABK in pediatric patients also describe weight-normalized Vd of ABK decreasing as an exponential function of age. 19, 25) In addition, we created a hypothetical factor``FAC1'' which describes the effect of difference of disease type on the pharmacokinetic parameters of TBPM in Equations 8 and 9, in order to examine differences in the CL/F and Vd/F between pediatric/otolaryngological infection and bacterial pneumonia. We created the hypothetical factor following a population pharmacokinetic analysis of ABK, in which discrimination in the pharmacokinetic parameters of the drug was reported in adult patients with different diseases such as pneumonia, sepsis and other disorders. 26) The effects of diseases on pharmacokinetics of drugs were assumed to be detectable, when compared with non-infectious state, as in the case of population pharmacokinetic analysis of ABK. 26) However, differences in the pharmacokinetics of drugs among different diseases were assumed to be difficult to detect, as in the case of the present population pharmacokinetic analysis of TBPM. After all, the population pharmacokinetic parameters of TBPM in pediatric patients, which we obtained by optimizing the Full Model constructed above, were simple but assessed to be robust and precise ( Table  5 , Fig. 5 ).
The secondary pharmacokinetic parameters (Tmax, Cmax, AUC0-24h and t1/2) of each pediatric patient were calculated on the basis of individual Bayesian estimates of the primary pharmacokinetic parameters. The parameters were then compared among three age groups (0.5-3, 3-6 and 6-16 years old). The average Cmax values in the 0.5-3 and 3-6 year-old groups were lower than those in the 6-16 year-old group at a dose of 6 mg/kg ( Table 6 ). We presumed it was because the population mean Vd/F of TBPM declined with age ( Table 4) . The average AUC0-24h values in the 0.5-3 and 3-6 year-old groups were smaller than those in the 6-16 year-old group at 4 mg/kg, and the average AUC0-24h value in the 0.5-3 year-old group was smaller than that in the 6-16 year-old group at 6 mg/kg ( Table 6 ). Weight-normalized glomerular filtration rates (GFR) (mL/min/kg) of children peak at about one year old and tend to decline afterwards. 27) In addition, the population mean CL/F of TBPM declined with decreasing weight-normalized Ccr ( Table  4) . Due to these factors, we assumed that the average AUC0-24h values of TBPM in the lower age groups (0.5-3 and 3-6 years old) were smaller than those in the higher age group (6-16 years old). The differences were, however, tiny (about 10-20% of the value in the higher age group), and thus we decided there was no need to adjust the dosage regimen of TBPM-PI according to age. The Cmaxf/MIC and the AUCf/MIC values, which were calculated by multiplying Cmax and AUC0-24h at doses of 4 and 6 mg/kg b.i.d. (Table 6 ) by serum free fraction (＝0.33) 16) and dividing them by MIC90's of causative pathogens (PRSP: 0.1 mg/mL, H.influenzae: 0.39 mg/mL) 6) thereafter, almost exceeded the target values (AUCf/MIC:10, Cmaxf/MIC:4). 16) Therefore, the dosage conditions adopted in the Phase II and Phase III studies 1, 2) were regarded as appropriate from the viewpoint of the PK/PD evaluation.
The AUC0-24h of TBPM in adult patients with otolaryngological infection was 14.9 mg･hr/mL after TBPM-PI administration at the recommended dosage regimen of 250 mg b.i.d., 15, 16) which corresponded to the dosage regimen in pediatric patients on the basis of dose per body weight. Likewise, the AUC0-24h of TBPM in pediatric patients in the whole range of childhood was 11.00±1.84 mg･ hr/mL after TBPM-PI administration of 4 mg/kg b.i.d.; this value after administration of 6 mg/kg b.i.d. was 16.07±3.35 mg･hr/mL ( Table 6 ). The AUC0-24h values of TBPM were similar in pediatric and adult patients. For this reason, the exposure of TBPM in pediatric and adult patients was not considered to be very different.
TBPM-PI is aimed at the treatment of prolonged or recurrent infections in pediatric patients due to PRSP and/or H.influenzae, which are difficult to be cured with the currently clinically available antibiotics. Therefore, TBPM-PI should be administered according to an optimum dosage regimen from the beginning of treatment, in order to achieve sufficient efficacy. We devised a proper method for ascertaining the appropriateness of the presently recommended clinical dosage (4 mg/kg b.i.d. and/or 6 mg/kg b.i.d.). Individual primary pharmacokinetic parameters (ka, CL/F, Vd/F and Tlag, kel＝ (CL/F)/(Vd/F)) are predicted based on the population mean parameters of TBPM obtained in this study (Table  4 ) and the patient's demographic data (weight-normalized Ccr and Age). The secondary pharmacokinetic parameters (Tmax, Cmax and AUC0-24h) are calculated using the predicted individual primary pharmacokinetic parameters and the recommended clinical dosage with Equations 11-13. The Cmax and AUC0-24h are multiplied by serum free fraction (＝0.33) 16) and divided by MIC90's of causative pathogens (PRSP: 0.1 mg/mL, H.influenzae: 0.39 mg/mL), 6) resulting in the PK/PD parameters (Cmaxf/MIC and AUCf/MIC). The calculated values are compared with the target values (AUCf/MIC:10, Cmaxf/MIC:4), 16) and the dosage is confirmed to be appropriate or adjusted to achieve sufficient efficacy, if necessary.
In conclusion, the population pharmacokinetic parameters of TBPM obtained in this study are useful information for verifying the validity of the presently recommended dosage of TBPM-PI in the clinical site. We hope that the information serves for proper use of TBPM-PI, a novel oral carbapenem antibiotic, in treatment of outpatients infected with drug-resistant pathogens. It would improve the quality of life (QOL) of patients and prevent the spread of drug-resistant pathogens, which contributes to medical services.
